RT @AurelieRheumo: HCQ does not prevent RA in CCP+ pts w/out clinical arthritis! Stop RA: RCT HCQ vs. PBO in pts at-ris

Aurelie Najm @AurelieRheumo Nov 13, 2022

HCQ does not prevent RA in CCP+ pts w/out clinical arthritis!

Stop RA: RCT HCQ vs. PBO in pts at-risk

Interim analysis 140+ pts
RA development HCQ 34% vs. PBO 36%

Trial interrupted as met futility criteria.

t.co/n31OmsjLhM

Abs#1604 #ACR22 @RheumNow #ACRBest

Hydroxychloroquine Does Not Prevent the Future Development of Rheumatoid Arthritis in a Population with Baseline High Levels of Antibodies to Citrullinated Protein Antigens and Absence of Inflammatory Arthritis: Interim Analysis of the StopRA Trial - ACR Meeting Abstracts

Article Rheumatoid Arthritis

ABA versus HCQ in Palindromic Rheumatism

Jack Cush, MD May 18, 2026

Palindromic rheumatism may develop rheumatoid arthritis (RA) and could be an at-risk population. A pilot trial compared abatacept (ABA) versus hydroxychloroquine and demonstrated ABA reduces RA development in a 2 year study. An open-label, multicenter, randomized trial enrolled 70 patients…

Article Rheumatoid Arthritis

Best of 2025: Hydroxychloroquine for Everyone

Jack Cush, MD Dec 29, 2025

Nearly 25 years ago, while lecturing on best therapies for rheumatoid arthritis (RA), I loudly stated that hydroxychloroquine was “useless” and, deservedly, I was “boo-ed” off stage. My point then was that rheumatologists needed to be aggressive, if not overly aggressive, in treating all RA patients. And my view was that HCQ was representative of under-treatment. I have reconsidered the use of HCQ in RA substantially in the last few years, based on its merit.